About PANHEMATIN

Reference Guide Icon

QUICK REFERENCE GUIDE FOR HEALTHCARE PROFESSIONALS

An acute intermittent porphyria (AIP) attack requires immediate attention. This guide provides quick access to information needed to treat an AIP patient during an acute attack.

View Quick Reference Guide

PANHEMATIN® is an FDA-approved medication that has been providing relief from attacks of AIP for over 40 years.1

PANHEMATIN is a hemin for injection indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate.1


How PANHEMATIN treats AIP attacks

During AIP attacks, the body's heme pool is depleted.2 PANHEMATIN helps replenish the heme pool, which represses the body's signaling to produce more heme. This allows heme production to slow and the accumulated neurotoxic porphyrin precursors to decline.3

AIP Attack Cycle

Watch how AIP Disrupts the Heme Cycle
and How Panhematin Works

Limitations of Use1

  • Before administering PANHEMATIN, consider an appropriate period of carbohydrate loading (i.e., 400 g glucose/day for 1 to 2 days).
  • Attacks of porphyria may progress to a point where irreversible neuronal damage has occurred. PANHEMATIN therapy is intended to prevent an attack from reaching the critical stage of neuronal degeneration. PANHEMATIN is not effective in repairing neuronal damage.

Clinical and chemical responses after PANHEMATIN infusions

5 open-label studies involving 72 patients and 127 courses of treatment supported the approval of PANHEMATIN3,4,5
85.5% of treatment courses had a positive clinical response and 100% of treatment courses had a positive chemical response1

clinical and chemical response chart *Clinical response defined as improvement of symptoms and reduction in pain. **Chemical response defined as reductions in δ-aminolevulinic acid (ALA) and/or porphobilinogen (PBG) levels

Results from an Observational Patient Reported Outcomes Study1

Study included 90 patients with AIP

55%

reported receiving hemin during acute attacks

74%

of these patients reported PANHEMATIN as being very successful in treating abdominal pain and other symptoms of AIP

50% reported having received treatment with opiates during an acute attack

44% of these patients reported that opiates were effective

safety badge icon

Safety Summary1

The most common adverse reactions (occurring in >1% of patients) are: headache, pyrexia, infusion site reactions, and phlebitis

Clinical Trials Experience: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of PANHEMATIN use was evaluated in a compassionate use study. A total of 130 patients were treated with hemin for acute attacks, prophylaxis or both. Of those, 111 patients were administered hemin for treatment of 305 acute porphyria attacks and to 40 patients for prophylaxis.

The majority (92%) of patients were Caucasian. Most (72%) were female; all adult patients had a mean age ± SD of 40.3 ± 12.3 years. Proportionally more females (15 out of 19) received prophylaxis or a combination of acute treatment and prophylaxis (19 out of 21).

For the treatment of acute attacks, patients received 2 to 4 mg/kg/day PANHEMATIN intravenously for 1 to 9 doses. For prophylaxis patients, the most common doses were weekly or biweekly infusions. The table below summarizes adverse reactions occurring in >1% of patients treated with PANHEMATIN, categorized by body system and order of decreasing frequency.


Adverse Reactions in >1% of Patients Treated with PANHEMATIN

adverse reactions graph

Order from your primary wholesaler or Cencora (formerly ASD Healthcare)

How to Order Panhematin

Weekend delivery available on request with an additional shipping cost

ORDERS PLACED BY

Monday-Thursday 6:30 PM CT

Friday 6:00 PM CT

Saturday Delivery

DELIVERED

UPS Next Day Air for 10:30am delivery

UPS Next Day Air for MONDAY 10:30am delivery

Saturday delivery must be requested when order is placed

Include any specific delivery instructions when ordering. New to ordering PANHEMATIN? Ask for expedited account setup.

PANHEMATIN is supplied as a sterile, lyophilized black powder in single dose dispensing vials (NDC 55292-702-54) in a carton (NDC 55292-702-55). The vial stopper contains natural rubber latex. Store lyophilized powder at 20-25°C (68-77°F).1

Clinical benefit from PANHEMATIN depends on prompt administration1

Resources for Patients Help Your Patients Access Support
Administration Guide and Ordering Get Step-by-Step Instructions

Important Safety Information